Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread

Journal of Virology

Volumn 86, Issue 8, 2012, Pages 4586-4598

  Awasthi, Sita ^a   Zumbrun, Elizabeth E ^a,c   Si, Huaxin ^a,d   Wang, Fushan ^a,e   Shaw, Carolyn E ^a   Cai, Michael ^a,f   Lubinski, John M ^a   Barrett, Shana M ^a,g   Balliet, John W ^b   Flynn, Jessica A ^b   Casimiro, Danilo R ^b   Bryan, Janine T ^b,h   Friedman, Harvey M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d Fraunhofer USA Inc   (United States)

^e WUXI APPTEC   (China)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g SALUS UNIVERSITY   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN D; GLYCOPROTEIN E; HERPES SIMPLEX VACCINE; LIVE VACCINE; PROTEIN C; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EPITHELIUM CELL; FEMALE; GENE DOSAGE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; MOUSE; NERVE ENDING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT INFECTION; SPINAL GANGLION; VAGINITIS; VIRUS DETECTION; VIRUS SHEDDING; VIRUS VIRULENCE; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DNA, VIRAL; FEMALE; GANGLIA, SPINAL; GENE DELETION; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; MICE, SCID; NEURONS; SPINAL CORD; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS;

ANIMALIA; CAVIA; HUMAN HERPESVIRUS 2; MUS;

EID: 84861362047     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07203-11     Document Type: Article

References (48)

1. Akhrameyeva NV, Zhang P, Sugiyama N, Behar SM, Yao F. 2011. Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J. Virol. 85:5036-5047.
2. Awasthi S, Lubinski JM, Eisenberg RJ, Cohen GH, Friedman HM. 2008. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 26:1195-1203.
3. Awasthi S, Lubinski JM, Friedman HM. 2009. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 27:6845-6853.
4. Awasthi S, et al. 2011. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J. Virol. 85:10472-10486.
5. Belshe RB, et al. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43.
6. Bourne N, et al. 2003. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187:542-549.
7. Bourne N, Stanberry LR, Bernstein DI, Lew D. 1996. DNA immunization against experimental genital herpes simplex virus infection. J. Infect. Dis. 173:800-807.
8. Boursnell ME, et al. 1997. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175:16-25.
9. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. 2008. A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J. Virol. 82:8431-8441.
10. Brown ZA, et al. 1997. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337:509-515.
11. Brown ZA, et al. 1987. Effects on infants of a first episode of genital herpes during pregnancy. N. Engl. J. Med. 317:1246-1251.
12. Brown ZA, et al. 2003. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 289:203-209.
13. Canziani G, et al. 1999. Exploring biomolecular recognition using optical biosensors. Methods 19:253-269.
14. Corey L, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
15. Corey L, Wald A, Celum CL, Quinn TC. 2004. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35:435-445.
16. de Bruyn G, et al. 2006. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24: 914-920.
17. Dix RD, McKendall RR, Baringer JR. 1983. Comparative neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral inoculation of BALB/c mice. Infect. Immun. 40:103-112.
18. Halford WP, et al. 2011. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 6:e17748.
19. Halford WP, Puschel R, Rakowski B. 2010. Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One 5:e12251.
20. Hoshino Y, et al. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79:410-418.
21. Hoshino Y, et al. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 200:1088-1095.
22. Hoshino Y, et al. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034-4040.
23. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. 1987. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N. Engl. J. Med. 316:1444-1449.
24. Lubinski JM, et al. 1998. Herpes simplex virus type 1 glycoprotein gC mediates immune evasion in vivo. J. Virol. 72:8257-8263.
25. McGraw HM, Awasthi S, Wojcechowskyj JA, Friedman HM. 2009. Anterograde spread of herpes simplex virus type 1 requires glycoprotein E and glycoprotein I but not Us9. J. Virol. 83:8315-8326.
26. McGraw HM, Friedman HM. 2009. Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites. J. Virol. 83:4791-4799.
27. Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B. 1987. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J. Infect. Dis. 155:921-930.
28. Meignier B, Martin B, Whitley RJ, Roizman B. 1990. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162:313-321.
29. Morello CS, Levinson MS, Kraynyak KA, Spector DH. 2011. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J. Virol. 85:3461-3472.
30. Nagashunmugam T, et al. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72: 5351-5359.
31. Prichard MN, et al. 2005. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23: 5424-5431.
32. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
33. Smith JS, Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186:S3-S28.
34. Stanberry LR, Burke R, Myers MG. 1988. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infect. Dis. 157:156-163.
35. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
36. Stanberry LR, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
37. Straus SE, et al. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463.
38. Straus SE, et al. 1997. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176:1129-1134.
39. Tal-Singer R, et al. 1995. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J. Virol. 69:4471-4483.
40. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. 2006. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80:5283-5291.
41. Thompson RL, Sawtell NM. 2001. Herpes simplex virus type 1 latencyassociated transcript gene promotes neuronal survival. J. Virol. 75:6660-6675.
42. Tirabassi RS, et al. 2011. A mucosal vaccination approach for herpes simplex virus type 2. Vaccine 29:1090-1098.
43. Wald A. 2006. Genital HSV-1 infections. Sex. Transm. Infect. 82:189-190.
44. Wald A, Link K. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185:45-52.
45. Wald A, Zeh J, Selke S, Ashley RL, Corey L. 1995. Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med. 333:770-775.
46. Wang F, et al. 2010. Herpes simplex virus type 2 glycoprotein E is required for efficient virus spread from epithelial cells to neurons and for targeting viral proteins from the neuron cell body into axons. Virology 405:269-279.
47. Xu F, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.
48. Yamamura J, et al. 2000. Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector. Gene Ther. 7:934-941.